CN101910198B - 与动物毛发选择性结合的抗体和用于动物的基于抗体的药物递送系统 - Google Patents

与动物毛发选择性结合的抗体和用于动物的基于抗体的药物递送系统 Download PDF

Info

Publication number
CN101910198B
CN101910198B CN200880124208.7A CN200880124208A CN101910198B CN 101910198 B CN101910198 B CN 101910198B CN 200880124208 A CN200880124208 A CN 200880124208A CN 101910198 B CN101910198 B CN 101910198B
Authority
CN
China
Prior art keywords
hair
antibody
antibodies
binding
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200880124208.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN101910198A (zh
Inventor
S·霍夫曼
H-J·哈曼
R·费希尔
S·希尔伯格
S·O·沃格尔
H·欣克尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Intellectual Property GmbH
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Intellectual Property GmbH, Bayer Schering Pharma AG filed Critical Bayer Intellectual Property GmbH
Publication of CN101910198A publication Critical patent/CN101910198A/zh
Application granted granted Critical
Publication of CN101910198B publication Critical patent/CN101910198B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nanotechnology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN200880124208.7A 2007-11-02 2008-10-29 与动物毛发选择性结合的抗体和用于动物的基于抗体的药物递送系统 Expired - Fee Related CN101910198B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07021396 2007-11-02
EP07021396.2 2007-11-02
PCT/EP2008/009110 WO2009056280A1 (en) 2007-11-02 2008-10-29 Antibodies which bind selectively to hair of animals and an antibody based drug delivery system for animals

Publications (2)

Publication Number Publication Date
CN101910198A CN101910198A (zh) 2010-12-08
CN101910198B true CN101910198B (zh) 2014-10-29

Family

ID=40157719

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880124208.7A Expired - Fee Related CN101910198B (zh) 2007-11-02 2008-10-29 与动物毛发选择性结合的抗体和用于动物的基于抗体的药物递送系统

Country Status (9)

Country Link
US (1) US20110263826A1 (enExample)
EP (1) EP2207806B1 (enExample)
JP (1) JP5386499B2 (enExample)
KR (2) KR20100102103A (enExample)
CN (1) CN101910198B (enExample)
AU (1) AU2008317953B2 (enExample)
CA (1) CA2704024C (enExample)
NZ (1) NZ585004A (enExample)
WO (1) WO2009056280A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2550863A1 (de) 2011-07-27 2013-01-30 Bayer Intellectual Property GmbH Aktivstoffhaltige Partikel auf Polyacrylat-Basis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987161A (en) * 1974-06-19 1976-10-19 The Procter & Gamble Company Composition and method for conditioning hair with hair antiserum
US5425937A (en) * 1990-06-04 1995-06-20 Kanebo, Ltd. Hair treatment composition and hair care product, both containing anti-keratin antibody, and production of anti-keratin antibody
US6123934A (en) * 1994-03-24 2000-09-26 Kao Corporation Hair cosmetic composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2978245B2 (ja) * 1990-03-05 1999-11-15 マリンクロット ベタリナリイ，インコーポレイテッド 寄生虫防除組成物ならびにその製造法および使用法
JPH06227955A (ja) * 1992-12-08 1994-08-16 Kanebo Ltd 染毛剤又は化粧料及び前処理剤並びに染毛方法
US7067499B2 (en) * 2002-05-06 2006-06-27 Hercules Incorporated Cationic polymer composition and its use in conditioning applications

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987161A (en) * 1974-06-19 1976-10-19 The Procter & Gamble Company Composition and method for conditioning hair with hair antiserum
US5425937A (en) * 1990-06-04 1995-06-20 Kanebo, Ltd. Hair treatment composition and hair care product, both containing anti-keratin antibody, and production of anti-keratin antibody
US6123934A (en) * 1994-03-24 2000-09-26 Kao Corporation Hair cosmetic composition

Also Published As

Publication number Publication date
JP2011502178A (ja) 2011-01-20
NZ585004A (en) 2012-04-27
US20110263826A1 (en) 2011-10-27
AU2008317953A1 (en) 2009-05-07
CN101910198A (zh) 2010-12-08
JP5386499B2 (ja) 2014-01-15
EP2207806A1 (en) 2010-07-21
HK1151300A1 (en) 2012-01-27
KR20150138405A (ko) 2015-12-09
CA2704024A1 (en) 2009-05-07
WO2009056280A8 (en) 2010-06-10
EP2207806B1 (en) 2013-04-10
WO2009056280A1 (en) 2009-05-07
KR20100102103A (ko) 2010-09-20
CA2704024C (en) 2016-05-31
AU2008317953B2 (en) 2014-03-20

Similar Documents

Publication Publication Date Title
JP4537060B2 (ja) 治療剤および他剤の送達のための炭水化物結合領域含有融合タンパク質、およびそれらを含む組成物
Li et al. Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas
JP6018753B2 (ja) Ｂｍｐ−６の調節によって鉄の恒常性を制御するための方法および組成物
US10702543B2 (en) Intranuclear protein transduction through a nucleoside salvage pathway
TWI357820B (en) High concentration antibody and protein formulatio
Zaman et al. Nanoparticle formulations that allow for sustained delivery and brain targeting of the neuropeptide oxytocin
US9155801B2 (en) Amino acid sequences which enhance peptide conjugate solubility
JP2002503676A (ja) Ｆｃレセプターのリガンドを使用するマクロファージ媒介性疾患の治療および診断
TW200930371A (en) Endoparasiticidal topical compositions
US20150098897A1 (en) Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma
CN101910198B (zh) 与动物毛发选择性结合的抗体和用于动物的基于抗体的药物递送系统
Schmidt et al. Efficacy of a 0.0584% hydrocortisone aceponate spray in presumed feline allergic dermatitis: an open label pilot study
Huang et al. Neuronal SNAP-23 is critical for synaptic plasticity and spatial memory independently of NMDA receptor regulation
HK1151300B (en) Antibodies which bind selectively to hair of animals and an antibody based drug delivery system for animals
Spitzova et al. Interactions between host biogenic amines and sand fly salivary yellow-related proteins
Brayden et al. Drug delivery systems in domestic animal species
White A diagnostic approach to the pruritic horse
GB2527026A (en) Veterinary composition
Koerselman et al. Characterization of single domain antibodies that target IL-1R and ef-fectively block IL-1 signaling as a potential DMOAD
WO2024155982A3 (en) Bispecific binding agents for use in companion animals
Baghirov Beyond the blood–brain barrier: the fate of transcytosed therapeutics
Jones Phage-GnRH Constructs for Population Control of Feral Animals: Evaluation in Cats
Navanukraw Contraception in free-ranging long-tailed macaques with special focus on anesthesia management and development of nanobody targeting extracellular domain of follicular stimulating hormone receptors
Foster et al. Veterinary dosage forms
Brayden peer reviewed

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1151300

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: BAYER ANIMAL HEALTH GMBH

Free format text: FORMER OWNER: BAYER PHARMACEUTICALS AG

Effective date: 20111221

C41 Transfer of patent application or patent right or utility model
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Berlin

Applicant after: BAYER PHARMA AG

Address before: Germany Leverkusen

Applicant before: Bayer Schering Pharma AG

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: BAYER SCHERING PHARMA AG TO: BAYER PHARMACEUTICALS AG

TA01 Transfer of patent application right

Effective date of registration: 20111221

Address after: Germany Leverkusen

Applicant after: BAYER ANIMAL HEALTH GmbH

Address before: Berlin

Applicant before: BAYER PHARMA AG

ASS Succession or assignment of patent right

Owner name: BAYER INTELLECTUAL PROPERTY GMBH

Free format text: FORMER OWNER: BAYER ANIMAL HEALTH GMBH

Effective date: 20130129

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130129

Address after: German Monheim

Applicant after: BAYER INTELLECTUAL PROPERTY GmbH

Address before: Germany Leverkusen

Applicant before: Bayer Animal Health GmbH

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1151300

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20141029

Termination date: 20171029

CF01 Termination of patent right due to non-payment of annual fee